Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab +/- Ligufalimab with Chemo in Gastric/GEJ Cancer
NCT05960955Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab, cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Nov 2023; status: recruiting.
02
Drugs
ligufalimabcadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05960955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05960955.